322 results found

We closed out July 2025 in Boston alongside several of our Axinn colleagues attending the American Conference Institute's 12th Annual Summit for Women Leaders in Life Sciences Law.

On October 31, 2023, FDA approved Amgen's Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Janssen's Stelara (ustekinumab). Stelara has been selected by the Center...

The continuing debate as to where to draw the line between encouraging innovation and lowering drug costs was front and center during a Senate HELP Committee confirmation hearing for NIH director...

According to Judge Gilstrap in the Eastern District of Texas, obligations to negotiate under fair, reasonable, and non-discriminatory (FRAND)...

In a report by IPlytics, published today, they have confirmed what most in the business already presumed: that ownership of 5G standard essential patents (SEPs)...

The International Trade Commission has undergone a fundamental shift over the past 18 months, with new precedent on domestic industry requirements and dramatic changes in filing patterns. This analysis examines how recent Federal Circuit decisions, USPTO policy reversals, and shifting government priorities are reshaping IP enforcement strategy at the ITC.

A great thing about patent litigation is the vast array of legal doctrines, arguments, and defenses that can come up in any given case.

In a recent Federal Register notice, the PTO announced a proposed rule requiring that any settlement agreement resolving a PTAB proceeding...

On April 30, 2024, the U.S. Patent and Trademark Office (PTO) issued a Request for Comment on how AI technology could affect the PTO's evaluation of patentability...

Over the past year, FTC has placed two sets of Orange Book listings in its crosshairs, but, to date, FTC has not actually begun any litigation on its own.

As we anticipated, the FTC has appealed Judge Kernodle's judgment in Chamber of Commerce v. Federal Trade Commission that vacated the FTC's new HSR Rule and Form.

FTC recently placed improper Orange Book patent listings squarely in its crosshairs. In its September 2023 policy statement, FTC announced that it would "scrutinize improper Orange Book listings"...

While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, managing partner Jeny Maier and partner James Hunsberger conducted one-on-one interviews for the Our Curious Amalgam podcast...

It was a tough day for opposing patent damages experts in Ecolab Inc. v. Dubois Chemicals, Inc., as Judge Andrews of the District of Delaware granted Daubert motions directed to both experts' reasonable royalty opinions.

Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I moderated on Industry Insights...

Last week, the Seventh Circuit heard arguments in Motorola Solutions, Inc. v. Hytera Communications Corp. concerning when, if at all, civil claims under the Defend Trade Secrets Act ("DTSA")...

On Sunday evening, CBS's 60 Minutes aired a segment featuring "The Five Eyes" and the critical issue of state-sponsored intellectual property ("IP") and trade secret theft.

Two healthcare providers face class action lawsuits challenging their use of anti-steering and anti-tiering contract provisions that allegedly prevent insurers from designing cost-effective healthcare plans. These follow-on cases emerge after government enforcement actions, with courts finding sufficient evidence of market power and anticompetitive effects to allow the litigation to proceed.